This article is more than 5 years old. Information may no longer be current.

Study shows implant safe in postcataract inflammation

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

IVeena Delivery Systems announced positive results from a pilot trial for its bioerodible implant for treatment of pain and inflammation after cataract surgery.

The implant, IVMED-10, is placed during cataract surgery and releases dexamethasone for 2 weeks. In the trial, eight patients were implanted with IVMED-10. The device was found to be safe and effective for control of inflammation, and retinal thickness outcomes were comparable to NSAID and steroid standard of care therapy, according to a press release from iVeena.

Adverse events included elevated IOP, corneal edema and pain, but all were transient in nature.

“The results of the study are very encouraging,” Jerry Simmons, CEO of iVeena, said in the release. “This study was designed to measure the safety of IVMED-10 and it met the primary objectives. These results support the ongoing clinical development of IVMED-10 and warrant further investigation into the intracapsular platform.”

The company is planning further study of IVMED-10 and a pilot study of IVMED-20 for 2018.